share_log

Kala Pharmaceuticals Q3 EPS $(3.41) Misses $(2.15) Estimate

Benzinga ·  Nov 13, 2023 08:11

Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(3.41) per share which missed the analyst consensus estimate of $(2.15) by 58.6 percent. This is a 61.77 percent increase over losses of $(8.92) per share from the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment